Katkin Keith 4

What Happened
Keith Katkin, a director of Syndax Pharmaceuticals (SNDX), received a grant of 24,000 restricted stock units (RSUs) on 2026-02-04. The Form 4 reports the award as an acquisition at $0.00 per share (total reported acquisition value $0). This transaction is a compensation grant (award), not an open‑market buy or sell.

Key Details

• Transaction date: 2026-02-04; Form 4 filed 2026-02-06 (appears timely).
• Transaction type/code: Award/Grant (A) — 24,000 RSUs at $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: RSUs vest one year from grant; underlying shares will not be delivered and may not be transferred or sold until the earlier of separation from service, death, disability, or change in control.
• No indication of a 10b5-1 plan, tax withholding sale, or late filing in this report.

Context
RSUs are a common form of director compensation and represent a future right to receive shares if vesting conditions are met. Because these RSUs vest in one year and were granted at $0, there was no cash purchase and no immediate increase in tradable shares. Awards like this are routine compensation disclosures and do not by themselves indicate the director is buying or selling stock for investment reasons.